Brillpharma Private Limited - Due diligence report

A 360° intelligence report on Brillpharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and dis…

2012-04-16 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
BP Brillpharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Brillpharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
71/100
Trust Score
Moderate

Brillpharma Private Limited is assessed as Moderate with a Trust Score of 71/100. Brillpharma Private Limited is an active private limited foreign company incorporated in india incorporated in 2012, operating in the Business Services sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Brillpharma Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
71/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
20/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
70/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 1 satisfied (3.75 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others1 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
THEMBALATH NARAYANAN KUTTY 01234567 Director 01/04/2018 6 yrs Approved
PRITI RAMACHANDRAN NAIR 01234567 Director 01/04/2018 6 yrs Approved
RAMACHANDRAN THEMBALATH MOOTHEDATH RAMANKUTTY NAIR 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Bristol Laboratories Ltd.
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Bristol Laboratories Ltd. Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 70
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Latest year revenue grew 1.42.
EPFO headcount growing - hiring signal.
Operating for 14+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Negative net worth.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment48/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view55/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 11 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
17 Mar 2022
Charge satisfied
Others
30 Sep 2016
Charge created
Others - 3.75 cr
30 Sep 2015
Director ceased
THEMBALATH NARAYANAN KUTTY
04 Sep 2015
Securities allotted
60937.00 Equity Shares - 2.44 cr raised
20 Mar 2015
Director appointed
THEMBALATH NARAYANAN KUTTY (Director)
26 Mar 2013
Securities allotted
17303.00 Equity Shares - 48.42 Lakh raised
16 Apr 2012
Incorporated
Registered with Roc Mumbai
Director appointed
PRITI RAMACHANDRAN NAIR (Director)
Director appointed
RAMACHANDRAN THEMBALATH MOOTHEDATH RAMANKUTTY NAIR (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Edifice Solutions Private Limited U45400TG2013PTC091928 Hyderabad, Telangana, India
Trident Staff Solutions Private Limited U74140KA2010PTC053368 Bangalore North, Karnataka, India
Neptune Engineering Private Limited U51505DL1987PTC027347 New Delhi, Delhi, India
Ambertag Analytics U72900KA2013PTC070926 Bangalore, Karnataka, India
Sailords Freight Private Limited U63000DL2014PTC271553 Delhi, Delhi, India
Gujral Tours And Travels Private Limited U74899DL1994PTC058179 New Delhi, Delhi, India
Next Tree Products Private Limited U74999MH2017PTC292162 Bhiwandi, Maharashtra, India
Gwalior Finance Corporation Limited U67190WB1948PLC210002 Kolkata, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Brillpharma Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Brillpharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 75/100, margin trends, ownership structure and peer set for Brillpharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 71/100, distress signals and MSME payment-delay disclosures - know whether Brillpharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Brillpharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Brillpharma Private Limited an active company?

Brillpharma Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Brillpharma Private Limited financially healthy?

Brillpharma Private Limited has a Financial Health Score of 20/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Brillpharma Private Limited?

Its overall Trust Score is 71/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Brillpharma Private Limited?

The ultimate holding entity is Bristol Laboratories Ltd.. 3 active director(s) are on record.

Does Brillpharma Private Limited have loans or charges against its assets?

No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Brillpharma Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Brillpharma Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.